About Penta
Who we are
Diversity and Inclusion
Our Network
Penta Foundation Italy
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Brighter Future Award
Archivio
Nelfinavir doses should be increased in infants less than 3 months
Current evidence for the use of pediatric antiretroviral therapy – a PENTA analysis
Variable use of therpaeutic interventions for children with human immunodeficiency virus type 1 infection in Europe.
Reconstitution of the T-cell Pool in Treated, HIV-infected Children
Immune repopulation after HAART in previously untreated HIV-1 infected children
A randomised trial evaluating three NRTI regimens with and without Nelfinavir in HIV-infected children: 48 week follow-up from the PENTA 5 trial
Drug resistance in a trial of nucleoside analogue and protease inhibitor therapy in children (PENTA 5)